TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHA): A Laboratory Classroom Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Newport Beach, California, United States, 92660
- Newport Beach Clinical Research Associates, Inc.
-
-
Nevada
-
Las Vegas, Nevada, United States, 89128
- Center for Psychiatry and Behavioral Medicine, Inc.
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center
-
-
Texas
-
Houston, Texas, United States, 77007
- Bayou City Research
-
Lubbock, Texas, United States, 79423
- Westex Clinical Investigation
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children aged 6 to 12 years with ADHD who require pharmacologic treatment for this condition
Exclusion Criteria:
- Other serious illnesses or conditions that would put the patient at particular risk for safety events or would interfere with treatment/assessment of ADHD
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
formulation without active moiety
|
|
Experimental: TRI102
Active, amphetamine extended-release oral suspension
|
formulation containing active moiety (amphetamine)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale)
Time Frame: Absolute change from baseline in SKAMP-C score from baseline to 4 hours after dose
|
Change from baseline in SKAMP-Combined Scores measured approximately 4 hours after dose (active or placebo).
The SKAMP-Combined score is obtained by summing 13 assessment items, where each item is rated on a 7-point scale (0 = normal to 6 = maximal impairment).
This gives an overall (combined) SKAMP Score of 0= normal to 78 which indicates maximal impairment.
The endpoint is assessed as a change from baseline in the overall score on the 78-point scale.
|
Absolute change from baseline in SKAMP-C score from baseline to 4 hours after dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PERMP (Permanent Product Measure of Performance).
Time Frame: Absolute change from baseline in PERMP questions answered correctly, measured from baseline to 4 hours postdose.
|
The PERMP is a math test that measures effortful performance without a learning curve (Wigal and Wigal 2006).
The test determines the number of problems attempted and the number of problems correctly answered.
In this study, the primary efficacy measure was a PERMP evaluation done 4 hours after taking study medication, a time selected a priori to coincide with the known pharmacodynamic effects based on prior research and to minimize the impact of repeated measures on adjustment of multiplicity (Wigal et al. 1998; Pelham et al. 2001).
The PERMP consists of 400 math questions and each are scored.
PERMP scores are expressed as the number of questions correct.
Predose PERMP Tests are compared with post-dose PERMP scores at prespecfied timepoints.
|
Absolute change from baseline in PERMP questions answered correctly, measured from baseline to 4 hours postdose.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sharon Wigal, PhD, Newport Beach Clinical Research Associates, Inc.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Neurologic Manifestations
- Dyskinesias
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Attention Deficit Disorder with Hyperactivity
- Hyperkinesis
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Sympathomimetics
- Adrenergic Uptake Inhibitors
- Amphetamine
Other Study ID Numbers
Other Study ID Numbers
- TRI102-ADD-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.